Gunung Jati General Hospital, Cirebon, West Java, Indonesia.
Gunung Jati General Hospital, Cirebon, West Java, Indonesia.
Indian Heart J. 2023 Jan-Feb;75(1):9-16. doi: 10.1016/j.ihj.2023.01.004. Epub 2023 Jan 13.
The benefit of prior statin use to reduce the incidence of arrhythmia in acute coronary syndrome (ACS) is still a matter of debate. Statins have multiple pleiotropic effects, which may reduce the incidence of in-hospital arrhythmia. A systematic review and meta-analysis were performed to evaluate prior statin use and the incidence of in-hospital arrhythmia in ACS.
This systematic review was conducted as per the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). We performed a literature search through Pubmed, Proquest, EBSCOhost, and Clinicaltrial.gov. A random-effect model was used due to moderate heterogeneity. Quality assessment was performed using Newcastle Ottawa Scale. Sensitivity analysis was performed by using leave one or two out method. PROSPERO registration number: CRD42022336402.
Nine eligible studies consisting of 86,795 patients were included. A total of 22,130 (25.5%) patients were in statin use before the index ACS event. The prevalence of old myocardial infarction, heart failure, hypertension, diabetes mellitus, and chronic renal failure and concomitant treatment with aspirin, clopidogrel, and beta blocker was higher in the prior statin group compared to no previous statin. Overall, prior statin use was associated with a significantly lower incidence of in-hospital arrhythmia during ACS compared to no previous statin (OR 0.60; 95% CI 0.49-0.72; P < 0.00001; I = 54%, P-heterogeneity = 0.03). In subgroup analysis, previous statin use reduced the incidence of atrial fibrillation or atrial flutter (OR 0.64; 95% CI 0.43-0.95; P = 0.03; I = 73%, P-heterogeneity = 0.01) and ventricular tachycardia or ventricular fibrillation (OR 0.57; 95% CI 0.49-0.65; P < 0.00001; I = 8%, P-heterogeneity = 0.35).
Based on aggregate patient data, prior statin use may reduce the incidence of in-hospital arrhythmia during ACS, particularly atrial fibrillation or atrial flutter and ventricular tachycardia or ventricular fibrillation.
他汀类药物在减少急性冠脉综合征(ACS)患者心律失常发生率方面的益处仍存在争议。他汀类药物具有多种多效性作用,可能降低住院期间心律失常的发生率。因此,我们进行了一项系统评价和荟萃分析,以评估 ACS 患者中既往他汀类药物的使用与住院期间心律失常的发生情况。
本系统评价按照 Preferred Reporting Items for Systematic Reviews and Meta-analyses(PRISMA)进行。我们通过 Pubmed、Proquest、EBSCOhost 和 Clinicaltrial.gov 进行了文献检索。由于存在中度异质性,因此使用随机效应模型。使用 Newcastle Ottawa Scale 进行质量评估。通过使用剔除一个或两个研究的方法进行敏感性分析。PROSPERO 注册号:CRD42022336402。
共纳入 9 项符合条件的研究,包含 86795 例患者。共有 22130(25.5%)例患者在 ACS 事件前使用了他汀类药物。与未使用他汀类药物的患者相比,既往使用他汀类药物的患者中陈旧性心肌梗死、心力衰竭、高血压、糖尿病和慢性肾功能衰竭的患病率更高,且同时使用阿司匹林、氯吡格雷和β受体阻滞剂的患者更多。总体而言,与未使用他汀类药物相比,ACS 期间使用他汀类药物与住院期间心律失常发生率显著降低相关(OR 0.60;95% CI 0.49-0.72;P<0.00001;I²=54%,P 异质性=0.03)。在亚组分析中,既往使用他汀类药物可降低心房颤动或心房扑动(OR 0.64;95% CI 0.43-0.95;P=0.03;I²=73%,P 异质性=0.01)和室性心动过速或心室颤动(OR 0.57;95% CI 0.49-0.65;P<0.00001;I²=8%,P 异质性=0.35)的发生率。
基于汇总患者数据,既往他汀类药物的使用可能会降低 ACS 患者住院期间心律失常的发生率,特别是心房颤动或心房扑动和室性心动过速或心室颤动。